Brookline Capital Upgrades Dare Bioscience, Cites Improved Funding
Brookline Capital: Upgraded Dare Bioscience (DARE.US) rating from holding to buying, with a target price of $3.00.
Dare Bioscience Analyst Ratings
Dare Bioscience Analyst Ratings
Brookline Capital: Downgraded Dare Bioscience (DARE.US) rating from buy to hold.
Dare Bioscience Analyst Ratings
Dare Bioscience Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $6 Price Target
HC Wainwright & Co. Maintains Buy on Dare Bioscience, Lowers Price Target to $6
Dare Bioscience Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $7 Price Target
Dare Bioscience Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $7 Price Target
Dare Bioscience Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $7 Price Target
HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $7 Price Target
HC Wainwright Raises Price Target on Dare Bioscience to $7 From $6, Reiterates Buy Rating
Dare Bioscience Analyst Ratings
Dare Bioscience Analyst Ratings
No Data